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Background More than 70 million people worldwide are estimated to have hepatitis C virus (HCV) infection. Emerging
evidence indicates an association between HCV and atherosclerotic cardiovascular disease. We aimed to determine
the association between HCV and cardiovascular disease, and estimate the national, regional, and global burden of
cardiovascular disease attributable to HCV.
Methods For this systematic review and meta-analysis, we searched MEDLINE, Embase, Ovid Global Health, and
Web of Science databases from inception to May 9, 2018, without language restrictions, for longitudinal studies that
evaluated the risk ratio (RR) of cardiovascular disease in people with HCV compared with those without HCV.
Two investigators independently reviewed and extracted data from published reports. The main outcome was
cardiovascular disease, defined as hospital admission with, or mortality from, acute myocardial infarction or stroke.
We calculated the pooled RR of cardiovascular disease associated with HCV using a random-effects model.
Additionally, we calculated the population attributable fraction and disability-adjusted life-years (DALYs) from HCVassociated cardiovascular disease at the national, regional, and global level. We also used age-stratified and sexstratified HCV prevalence estimates and cardiovascular DALYs for 100 countries to estimate country-level burden
associated with HCV. This study is registered with PROSPERO, number CRD42018091857.
Findings Our search identified 16 639 records, of which 36 studies were included for analysis, including 341 739 people
with HCV. The pooled RR for cardiovascular disease was 1·28 (95% CI 1·18–1·39). Globally, 1·5 million
(95% CI 0·9–2·1) DALYs per year were lost due to HCV-associated cardiovascular disease. Low-income and middleincome countries had the highest disease burden with south Asian, eastern European, north African, and Middle
Eastern regions accounting for two-thirds of all HCV-associated cardiovascular DALYs.
Interpretation HCV infection is associated with an increased risk of cardiovascular disease. The global burden of
cardiovascular disease associated with HCV infection was responsible for 1·5 million DALYs, with the highest burden
in low-income and middle-income countries.
Funding British Heart Foundation and Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license.

Introduction
Globally, more than 70 million people are estimated to
have hepatitis C virus (HCV) infection.1 Prevalence of
HCV is particularly high in the eastern Mediterranean
region and Europe, where approximately 2·3% and 1·5%
of the general population have HCV infection,
respectively.1 In the USA, the estimated prevalence of
past or current HCV infection is 1·4%, affecting
4·6 million people, of whom at least 3·5 million have
active HCV infection (1% of the general population).2
The number of new incident cases of HCV infections in
the USA has been increasing since 2010.3
After acute HCV infection, most patients develop
chronic infection.4 Usually, these patients remain
asymptomatic, with less than a third progressing to liver

cirrhosis in the subsequent 20–30 years.4 Although
mortality due to cirrhosis and hepatocellular carcinoma
are well recognised long-term complications of chronic
HCV infection,5,6 patients with chronic infection are also
at increased risk of non-liver-related mortality, including
cancer and circulatory death.7
Atherosclerotic cardiovascular disease is the most
common cause of death worldwide and the burden of
disease is projected to rise substantially over the next few
decades, particularly in low-income and middle-income
countries (LMICs).8 HCV transmission is also projected
to rise considerably in LMICs due to unsafe health-care
practices and injection drug use.9–11 Published data12–14
suggest that the long period of chronic HCV infection
might lead to the development of atherosclerotic
www.thelancet.com/gastrohep Vol 4 October 2019
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Research in context
Evidence before this study
We searched PubMed from database inception to Jan 1, 2018,
for systematic reviews and meta-analyses evaluating the
association between hepatitis C virus (HCV) infection and
atherosclerotic cardiovascular disease using the search terms
“myocardial infarction”, “stroke”, “cerebrovascular disease”,
“cardiovascular disease”, and “hepatitis C”. We found no studies
that assessed the risk of cardiovascular disease or calculated the
burden from all major atherosclerotic cardiovascular events
associated with hepatitis C. Previous meta-analyses have
evaluated the association between HCV infection and stroke
and surrogate markers of subclinical atherosclerotic disease.
Added value of this study
To our knowledge, our study is the first meta-analysis to
investigate the risk of major atherosclerotic cardiovascular

cardiovascular disease because of derangements in
metabolic pathways and chronic inflammation. However,
the direction and strength of the association between
HCV infection and cardiovascular disease remains
uncertain.15–19
Our study aimed to determine the association between
HCV infection and the risk of cardiovascular disease to
establish the global burden of cardiovascular disease
attributable to HCV.

Methods

Search strategy and selection criteria
We searched MEDLINE, EMBASE, Ovid Global Health,
and Web of Science from database inception to May 9,
2018, for original peer-reviewed articles using the search
terms “myocardial infarction”, “stroke”, “cerebrovascular
disease”, “cardiovascular disease”, and “hepatitis C” with
no language restrictions. Full search terms are in the
appendix (pp 2, 3). Additionally, we manually searched
relevant review articles and bibliographic reference lists
of studies selected for inclusion in our meta-analysis.
We included all longitudinal studies (case-control
studies, cohort studies, and randomised controlled trials)
that reported risk ratios (RRs) for hospital admission due
to atherosclerotic cardiovascular disease or cardiovascular
mortality in people with HCV compared with people
without HCV. When there were multiple publications
using data from the same cohort, we selected the article
that reported the longest follow-up period. Detailed fulltext review and data extraction was done independently
by at least two investigators (KKL, DS, RB, or MA) and
any disagreements were resolved by a third investigator
(ASVS). We contacted authors for additional data or
clarification if required. This study was done in
accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (appendix pp 4, 5).20 The study protocol is
available online.
www.thelancet.com/gastrohep Vol 4 October 2019

disease in people with HCV infection and to estimate the
burden of atherosclerotic cardiovascular disease attributed to
HCV infection at the global, regional, and national level.
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Implication of all the available evidence
Our findings show that people with HCV infection have a
higher risk of cardiovascular disease than those without.
The global burden of cardiovascular disease attributable to
HCV accounted for a substantial number of disability-adjusted
life-years in 2015, and the majority of the burden was borne
by low-income and middle-income countries. These finding
highlights the importance of public health strategies to
eradicate HCV infection to reduce the burden of not only
hepatic, but extrahepatic complications (such as
cardiovascular disease), especially in regions with high HCV
prevalence.

For studies that stratified the study population
according to the presence of HCV RNA viraemia, we
used the RR estimates pertaining to individuals who
were HCV RNA positive. We defined a cardiovascular
event as hospital admission with, or mortality from,
acute myocardial infarction or stroke. Studies that
evaluated a composite of acute cardiovascular events that
included myocardial infarction or stroke but were not
exclusive to these conditions were also included. For
studies that stratified stroke events into haemorrhagic
and ischaemic strokes, we included only ischaemic
strokes in the analysis because haemorrhagic strokes
physiological mechanisms that are
have distinct patho
unrelated to atherosclerosis.21

Data analysis
We extracted RR estimates comparing cardiovascular
events in people with HCV versus those without HCV
from published reports using a standardised data
extraction sheet. We estimated pooled RRs with
95% CIs. Since this outcome was relatively uncommon,
we pooled studies that reported odds ratio and RR. We
also assumed independence between risk estimates for
different endpoints reported within studies, consistent
with our previous analysis.22 We did a subgroup analysis
stratified by outcome, HIV co-infection, publication
year, risk of bias, definition of outcome event, and
geographical location.
Two independent investigators (KKL and DS) assessed
individual studies for risk of bias, using the degree of
adjustment for confounders as the primary domain, and
any disagreements were adjudicated by a third investigator.
Studies that had adjusted for age, sex, and at least one
other confounder were classified as being at low risk of
bias. Studies that adjusted for fewer confounders than this
were classified as moderate or high risk: studies that
adjusted for either age or sex without any other con
founders were classified as moderate risk of bias and

See Online for appendix

For study protocol see https://
www.crd.york.ac.uk/prospero/
display_record.
php?RecordID=91857
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16 639 records identified by database search

11 additional records identified
via bibliographic search

attributable fraction (PAF) for cardiovascular disease
attributable to HCV was calculated as described
previously:25,26

Population attributable fraction =
2270 duplicates removed

14 380 records identified for title and abstract screening

14 037 articles excluded

343 full-text articles assessed for eligibility

307 excluded after full-text
screening
83 different study design
or review paper
62 wrong outcomes
53 abstract only
46 wrong patient
population
35 duplicate articles
15 wrong comparator
11 insufficient data
2 duplicates

36 studies included in quantitative synthesis

Figure 1: Study selection

For more on the Polaris
Observatory see http://
polarisobservatory.org/

For the extraction databases,
data used to derive pooled
estimates, burden estimates,
and R code script see https://
github.com/kk-lee/hcv
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those that did not adjust for both age or sex were classified
as high risk of bias. We did the subgroup analysis stratified
by risk of bias.
We estimated the burden of cardiovascular disease
attributable to HCV at the national, regional, and global
level. We obtained 2015 global prevalence estimates of
viraemic HCV (HCV RNA positive) for 100 countries
from the Polaris Observatory, with estimates stratified by
Global Burden of Disease region.23 These 100 countries
represent more than 85% of the global population and
where more than 89% of all HCV viral infections (HCV
RNA positive) are estimated to occur worldwide.23 The
national prevalence estimates obtained were age-specific
and sex-specific. We obtained age-specific and sex-specific
disability-adjusted life-year (DALY) estimates for cardio
vascular disease (DALYs due to ischaemic heart disease
and stroke) for all adults aged older than 20 years in 2015
from the Institute of Health Metrics and Evaluation.24 The
extraction databases from the systematic review and the
data from the Polaris Observatory and Institute of Health
Metrics and Evaluation used to derive the pooled
estimates and the burden estimates alongside the R code
script are available online.
We estimated the population attributable risk fraction
at the national, regional, and global level using the pooled
RR for cardiovascular disease in patients with hepatitis C
and the prevalence estimates of HCV. The population

Prevalence × (RR – 1)
1 + (Prevalence × RR)

We then used national, regional, and global level
attributable fractions to calculate the burden as previously
described (appendix pp 6–10):
DALYs attributable to HCV=Cardiovascular DALYs × PAF
We provided estimates of PAF and burden in 5-year
age groups and presented data graphically using a linear
model to interpolate the intervening years. We further
provided burden estimates by income of nation stratified
by high-income versus LMICs. National income status
was defined according to the 2018 World Bank
classification.27
We anticipated heterogeneity in the RRs across studies
because of differences in study design, patient population,
geographical location, statistical methods, and adjustment
for confounders. We pooled RRs using a random effects
model to account for within and between study hetero
geneity. We assessed heterogeneity in the pooled metaestimate of the RR using the I² statistic. We assessed
publication bias using visual inspection of funnel plots of
the RR estimates and using Egger’s regression test for
asymmetry.28 We corrected for asymmetry using Duval and
Tweedie’s trim and fill method.29 Full statistical methods
are in the appendix (pp 6–10). All analyses were done using
R (version 3.4.1). A two-sided p value of less than 0·05 was
considered to indicate statistical significance.

Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had full
access to all the data in the study and had final
responsibility for the decision to submit for publication.

Results
We identified 16 650 articles, of which 2270 were
duplicates (figure 1). 343 full-text articles were assessed
for eligibility. After full-text review, 36 studies,7,30–64 which
provided 47 estimates, were included in our analyses
(table). These studies included 341 739 people with HCV.
31 (86%) of 36 studies were done in North America,
Europe, and east Asia. Only two studies30,31 originated
from LMICs. Most studies used the International
Classification of Diseases coding or physician diagnosis
to define the outcome events.
24 studies defined HCV infection as anti-HCV antibody
seropositivity, nine studies used detectable HCV RNA
levels, and three studies did not explicitly define their
approach (table). Overall, the meta-analysis showed that
www.thelancet.com/gastrohep Vol 4 October 2019
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Mean age Study
at baseline, period
years

Hepatitis C
virus status

1996
(73%)

50·9

2004–14

Seropositive Cardiovascular
disease

Undefined

369

3248
(79%)

45

1997–2013

Seropositive Stroke*

ICD-9

171 726

5949

171 726
(100%)

54

2001–15

Viraemic

ICD-9

Veterans Health
Administration

168 256

11 753

168 256
(100%)

55

2001–14

Seropositive Cardiovascular
disease

ICD-9

Hospital records

76 689

6790

45 016
(59%)

62·5

1996–2015

Seropositive Cardiovascular
disease,
myocardial
infarction, stroke

Undefined

5006

143

3624
(72%)

50

1994–2014

Seropositive Cardiovascular
disease*

Physician
diagnosis

Hospital records

143

19

101
(71%)

55

2005–10

Undefined

Cardiovascular
disease

Undefined

Cohort
study

Hospital register

1066

29

842
(79%)

42·7

2004–15

Viraemic

Cardiovascular
disease†

Physician
diagnosis

Taiwan

Cohort
study

National Health
Insurance Research
Database

69 915

848

35 936
(51%)

54·7

1998–2008

Undefined

Myocardial
infarction

Undefined

··

Australia

Cohort
study

Pharmaceutical Drugs
of Addiction System

29 571

122

20 403
(69%)

26

1993–2007

Seropositive Cardiovascular
disease

ICD-9,
ICD-10

Enger et al,
201442

ORD

USA

Cohort
study

Optum Research
Database (insurance
plans)

90 931

534

56 740
(62%)

49

2000–06

Seropositive Myocardial
infarction, stroke

ICD-9

Gillis et al,
201443

OCS

Canada

Cohort
study

Clinic register

4152

167

3483
(84%)

36

1995–2011

Seropositive Cardiovascular
disease†

Physician
diagnosis

Hsu et al,
201444

··

Taiwan

Cohort
study

National Health
Insurance Research
Database

7055

429

4599
(65%)

54·9

2003–11

Seropositive Myocardial
infarction, stroke

ICD-9

Pothineni
et al, 201445

UAMS

USA

Cohort
study

Enterprise Data
Warehouse at University
of Arkansas for Medical
Sciences

23 050

951

12 631
(55%)

50·9

2001–13

Viraemic

Cardiovascular
disease

ICD-9

Tripathi et al,
201446

··

USA

Cohort
study

Medicaid

13 632

1284

7661
(56%)

38

1994–2011

Seropositive Cardiovascular
disease

ICD-9

Womack et al,
201447

Veterans
Aging
Cohort
Study–
virtual
cohort

USA

Cohort
study

Veterans Health
Administration,
Medicare, Medicaid, and
Quality Enhancement
Research Initiative in
ischaemic heart disease

2187

86

0

43·6

2003–09

Seropositive Cardiovascular
disease*

ICD-9

Adinolfi et al,
201348

··

Italy

Casecontrol
study

Hospital records

820

123

524
(64%)

76

2010–12

Seropositive Stroke

Physician
diagnosis

Hsu et al,
201349

LHID2000

Taiwan

Cohort
study

Longitudinal Health
Insurance Database
2000

15 565

NR

8078
(52%)

Not
reported

2004–07

Viraemic

Stroke

ICD-9

Younossi et al, NHANES III
201350

USA

Cohort
study

National Health and
Nutrition Examination
Survey

8985

NR

4178
(46%)

Not
reported

1988–2006

Viraemic

Cardiovascular
disease

ICD-10

Campbell et al, ··
201251

UK

Cohort
study

Hospital records

4068

32

4068
(100%)

36·5

2004–09

Seropositive Cardiovascular
disease*

Physician
diagnosis

Carrieri et al,
201252

France

Cohort
study

Medical questionnaires

1154

49

900
(78%)

37·7

1997–2010

Seropositive Cardiovascular
disease*

ICD-10

Cohort
name

Country or Study
region
type

Data source

Heo et al,
201833

··

USA

Cohort
study

Organ Procurement and
Transplant Network

2728

117

Alvaro-Meca
et al, 201734

··

Spain

Casecontrol
study

Spanish Minimum Basic
Data Set

4091

Butt et al,
201735

ERCHIVES

USA

Cohort
study

Veterans Health
Administration

Chew et al,
201736

ERCHIVES

USA

Cohort
study

Goodkin et al,
201730

DOPPS

Multiple†

Cohort
study

Kovari et al,
201737

··

Switzerland Cohort
study

Swiss HIV Cohort Study

Piazza et al,
201638

··

USA

Cohort
study

FernandezMontero et al,
201539

··

Spain

Tsai et al,
201540

NHIRD–HCV

Vajdic et al,
201541

APROCOCOPILOTE

Participants, Events, Men, n
n
n
(%)

Outcome

Myocardial
infarction

Outcome
definition

(Table continues on next page)
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Cohort
name

Country or Study
region
type

Data source

Participants, Events, Men, n
n
n
(%)

Mean age Study
at baseline, period
years

Hepatitis C
virus status

Outcome

Outcome
definition

(Continued from previous page)
Forde et al,
201253

THIN

UK

Cohort
study

General practice
medical records

76 477

264

46 727
(61%)

38·6

1996–2008

Undefined

Myocardial
infarction

Read
diagnostic
code

Lee et al,
201254

REVEAL–
HCV

Taiwan

Cohort
study

Questionnaires and
interviews

19 636

477

9523
(48%)

47·6

1991–2008

Viraemic

Cardiovascular
disease

ICD-9

Liao et al,
201255

NHIRD

Taiwan

Cohort
study

National Health
Insurance Research
Database

20470

1981

10235
(50%)

52

2002–08

Viraemic

Stroke

ICD-9

Freiberg et al,
201156

Veterans
Aging
Cohort
Study–
virtual
cohort

USA

Cohort
study

Veterans Aging Cohort
Study and Large Health
Study of Veteran
Enrollees

8579

194

8579
(100%)

48·1

2000–07

Seropositive Cardiovascular
disease*

ICD-9

Kristiansen
et al, 201157

··

Norway

Cohort
study

Department of
Microbiology,
University Hospital of
North Norway

1010

5

686
(68%)

40

1990–2000

Seropositive Cardiovascular
disease

ICD-10

Ohsawa et al,
201158

KAREN

Japan

Cohort
study

KAREN cohort

1077

194

682
(63%)

60·4

2003–08

Seropositive Cardiovascular
disease

ICD-10

Bedimo et al,
201059

HIV Clinical
Care
Registry

USA

Cohort
study

Veterans Registry

19 424

1146

18 938
(97%)

46·2

1984–2004

Viraemic

ICD-9

Belloso et al,
201031

LATINA

Brazil,
Mexico

Cohort
study

LATINA cohort

160

40

Not
Not
reported reported

1997–2007

Seropositive Cardiovascular
disease*

Physician
diagnosis

DAD Study
Group, 201060

DAD study

Europe,
USA,
Australia

Cohort
study

DAD cohort

21 815

517

16 143
(74%)

38

1999–2007

Seropositive Myocardial
infarction*

WHO
MONICA
Project

Lee et al,
201061

··

Taiwan

Cohort
study

National Death
Certification Registry

23 665

22

11 879
(50%)

47·1

1991–92

Viraemic

ICD-9

Tsui et al,
200932

The Heart
and Soul
study

USA

Cohort
study

Veterans
Administration
electronic records

981

151

803
(82%)

66·3

2000–06

Seropositive Cardiovascular
disease

Physician
diagnosis

Guiltinan et al, ··
200862

USA

Cohort
study

Blood Systems

20 518

88

13 254
(65%)

Not
reported

1991–2002

Seropositive Cardiovascular
disease

ICD-9 CM,
ICD-10 CM

KalantarZadeh et al,
200763

··

USA

Cohort
study

DaVita outpatient
dialysis database

13 664

NR

7433
(54%)

60·1

2001–04

Seropositive Cardiovascular
disease

Undefined

Arcari et al,
200664

··

USA

Casecontrol
study

Clinical registry

75 834

292

47 775
(63%)

40·2

1991–2000

Seropositive Myocardial
infarction

ICD-9

Amin et al,
20067

··

Australia

Cohort
study

New South Wales
Health Department
Notifiable Diseases
Database

582

450

582
(100%)

34

1990–2002

Seropositive Cardiovascular
disease

ICD-9 and
ICD-10

Myocardial
infarction,
stroke*

Stroke

ICD=International Classification of Diseases. ERCHIVES=Electronically Retrieved Cohort of Hepatitis C Virus Infected Veterans. DOPPS=Dialysis Outcomes and Practice Patterns Study. NHIRD–HCV=National Health
Insurance Research Database–Hepatitis C Virus. ORD=Optum Research Database. OCS=Ontario HIV Treatment Network Cohort Study. UAMS=University of Arkansas for Medical Sciences. LHID2000=Longitudinal
Health Insurance Database 2000. NR=not reported. NHANES III=National Health and Nutrition Examination Survey III. APROCO-COPILOTE=Antiprotéases Cohorte. THIN=The Health Improvement Network.
REVEAL–HCV=Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–Hepatitis C Virus. DAD=Data Collection on Adverse Events of Anti-HIV Drugs. MONICA=Multinational Monitoring of
Trends and Determinants in Cardiovascular Disease. CM=Clinical Modification. *Risk ratio reported for hepatitis C virus and HIV co-infection versus HIV infection only. †Australia, Belgium, Canada, mainland
China, France, Germany, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Italy, Japan, New Zealand, Spain, Russia, Sweden, Turkey, the UK, and the USA.

Table: Baseline characteristics of studies included in the meta-analysis

individuals with HCV had a higher risk of cardiovascular
disease than individuals without HCV (pooled RR 1·28,
95% CI 1·18–1·39; figure 2). When stratified by outcome
the risk ratio was 1·13 (95% CI 1·00–1·28) for myocardial
infarction, 1·38 (1·19–1·60) for stroke, and 1·39
(1·24–1·55) for cardiovascular mortality (appendix p 11).
798

Individuals with HCV and HIV co-infection had a higher
risk of cardiovascular disease than those with HIV monoinfection (RR 1·20, 1·09–1·32). Post-hoc analyses showed
that the RR estimates from studies published before
2014, which was the median publication year, were
marginally higher than those from studies published
www.thelancet.com/gastrohep Vol 4 October 2019
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A

Cardiovascular events

Amin et al (2006)7
Kalantar-Zadeh et al (2007)63
Guiltinan et al (2008)62
Tsui et al (2009)32
Belloso et al (2010)31
Freiberg et al (2011)56
Freiberg et al (2011)56
Kristiansen et al (2011)57
Ohsawa et al (2011)58
Lee et al (2012)54
Carrieri et al (2012)52
Younossi et al (2013)50
Younossi et al (2013)50
Gillis et al (2014)41
Tripathi et al (2014)46
Womack et al (2014)47
Fernandez-Montero et a (2015)39
Vajdic et al (2015)41
Piazza et al (2016)38
Goodkin et al (2017)30
Chew et al (2017)36
Kovari et al (2017)37
Heo et al (2018)33
Pooled (I2=59·9%)

n/N

RR (95% CI)

450/75834
NR/13664
88/20518
151/981
40/160
129/8579
65/8579
5/1010
194/1077
477/19 636
49/1154
NR/701
NR/8284
167/4152
1284/13 632
86/2187
29/1066
122/29 571
19/143
6790/76 689
11 753/168 256
143/5006
117/2728

1·30 (1·20–1·50)
1·14 (0·94–1·36)
2·21 (1·41–3·46)
1·74 (0·92–3·32)
2·64 (0·65–10·80)
1·15 (0·77–1·71)
1·60 (1·03–2·48)
1·18 (0·38–2·74)
1·33 (0·84–2·11)
1·53 (1·05–2·23)
1·16 (0·59–2·29)
3·34 (0·55–20·50)
0·71 (0·23–2·21)
1·44 (0·97–2·13)
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Figure 2: Forest plots of pooled RRs for cardiovascular disease in people with hepatitis C virus versus people without
Pooled RRs for composite cardiovascular events (A), myocardial infarction (B), and stroke (C). n=number of events. N=number of participants. RR=risk ratio. NR=not
reported. df=degrees of freedom. DAD=Data Collection on Adverse Events of Anti-HIV Drugs.
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Figure 3: DALYs per 100 000 people for cardiovascular disease attributable to HCV
Grey colour denotes regions for which no HCV prevalence data were available to estimate burden. HCV=hepatitis C virus. DALYs=disability-adjusted life-years.

300

Low-income and middle-income countries
High-income countries

DALYs (thousands)

200

100

0

0

20

30

40

50

60

70

80

Age (years)

Figure 4: DALYs for cardiovascular disease attributable to hepatitis C virus
Solid lines show the central estimate and dashed lines show the 95% CI. DALYs=disability-adjusted life-years.

after 2014 (1·39 [1·25–1·54] vs 1·22 [1·11–1·34]). Studies
that ascertained outcome with physician diagnosis had
higher RRs than did those that used International
Classification of Diseases codes (1·68 [1·24–2·29] vs
1·31 [1·20–1·42]). Nine studies in patients with HCV
viraemia had marginally higher RRs than the overall
pooled RR (1·32, 1·15–1·51). Nearly two-thirds of studies
originated from the USA or Taiwan (21 [58%] of
36 studies). In the subgroup analysis, studies from these
two countries had a similar pooled RR as those from the
rest of the world (1·28 [1·16–1·40] vs 1·29 [1·12–1·48]
respectively).
800

There was significant heterogeneity (I²=77·5%) and
publication bias in the overall estimate (Egger’s test
p=0·003). Using the trim and fill method to correct for
funnel plot asymmetry did not change the direction of
effect but did attenuate the effect size (appendix p 20).
11 studies were at moderate or high risk of bias (appendix
pp 12, 13). Compared with studies with a low risk of bias,
those with moderate or high risk of bias had a similar
pooled RR (1·30 [95% CI 1·10–1·55] for studies with
moderate or high risk of bias vs 1·29 [1·19–1·40] for
studies with low risk of bias).
We estimated that in 2015, 1·5 million (95% CI
0·9–2·1) DALYs from cardiovascular disease were
attributable to HCV, with marked geographical
variation in the estimated burden. LMICs had the
highest disease burden, with South Asia, eastern
Europe, north Africa, and the Middle East accounting
for nearly two-thirds of the global burden of
cardiovascular disease attributable to HCV in 2015
(920·7 thousand DALYs; appendix p 14).
Of the 100 countries with available age-specific and
sex-specific viraemic HCV prevalence estimates for
2015, the highest burden (ie, cardiovascular DALYs
attributable to HCV) was in Ukraine, Mongolia, Gabon,
and Egypt (figure 3; appendix pp 15–17). Worldwide, the
PAF of cardiovascular disease attributable to HCV was
highest in people aged 55–59 years (appendix p 18).
DALYs from cardiovascular disease attributable to HCV
was highest in people aged 70–74 years (appendix p 18).
The burden of cardiovascular disease attributable to
HCV was higher in LMICs than in high-income
countries (1·4 million [95% CI 0·88–1·95] DALYs vs
0·1 million [95% CI 0·07–0·12] DALYs; figure 4;
appendix p 19).
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Discussion
In this systematic review and meta-analysis, we assessed
the association between HCV and cardiovascular disease
and estimated the global, regional, and national burden
of cardiovascular disease attributable to HCV. We made
several key observations. First, people with HCV have an
increased risk of cardiovascular disease compared with
those without HCV (RR 1·28). When stratified by type of
cardiovascular event, the overall pooled estimate was
higher for stroke than for myocardial infarction. Second,
our pooled risk estimate was derived from 341 739 people
with HCV infection included in 36 studies from
51 countries. Only two studies30,31 reported findings from
populations of LMICs, highlighting the paucity of data
from these regions. Third, the most up-to-date annual
global burden of cardiovascular disease attributable to
HCV was 1·5 million DALYs. Most of this burden was
concentrated in the 55–75 year age group, reflecting
more premature development of cardiovascular disease
in people with HCV. Fourth, considerable geographical
variation was identified in the burden of cardiovascular
disease attributable to HCV, with the highest burden
observed in south Asia, eastern Europe, north Africa, and
the Middle East. The majority of the burden was borne by
LMICs rather than high-income countries. This
observation is likely to reflect both a high prevalence of
chronic hepatitis C in these regions and an increasing
burden of cardiovascular disease.
Our analysis has several strengths. We included
longitudinal studies that evaluated the association
between HCV and hospital admissions with, or mortality
from, cardiovascular disease. Furthermore, the endpoint
of our analysis was major adverse cardiovascular events,
which enabled accurate risk estimation and assessment
of cardiovascular burden. Previous systematic reviews
and meta-analyses,65–67 which included cross-sectional
studies and studies that used surrogate endpoints that
might not be fully reflective of a causal relationship, have
reported divergent findings. We also analysed burden
using age-specific, sex-specific, and country-specific
cardiovascular burden and HCV prevalence estimates,
allowing us to provide HCV attributable burden estimates
for specific age groups, which could be useful for policy
makers. Moreover, our estimates for HCV prevalence
obtained from the Polaris Observatory23 reflect viraemia
rather than just seropositivity alone, and the countries
for which we had prevalence estimates accounted for
over 89% of all chronic HCV infections globally. Our
estimates for the PAF and subsequent HCV associated
cardiovascular burden are therefore based on a high-risk
population with active HCV infection, in whom both
long-term hepatic and extrahepatic complications remain
common.
This study has a number of limitations. Most studies
included in this meta-analysis originated from highincome countries in North America and western Europe,
but estimates were applied to all regions. This approach
www.thelancet.com/gastrohep Vol 4 October 2019

is commonly used in this type of analysis because of
paucity of data from LMICs.68,69 This highlights an
ongoing need for research in these low-resource settings,
in which the disease prevalence of HCV and cardio
vascular disease is high, to improve the accuracy of the
burden estimates in these regions. We also observed
significant heterogeneity in our RR estimates. However,
the direction of effect was consistent and robust across
all subgroup analyses. The observed heterogeneity is
likely to reflect the diverse patient population, viraemic
status of the study population, differences in health-care
systems, access to treatment, and geographical location
of the studies pooled in this analysis. Many studies did
not fully account for the competing risk of noncardiovascular mortality, thus some methodological
heterogeneity exists. Most people with HCV infection die
from non-cardiovascular causes,7,70 therefore this is an
important competing risk that might distort the
exposure–outcome association with cardiovascular
disease. People with HIV and HCV co-infection have a
higher risk for cardiovascular disease than those with
HIV mono-infection. This increased risk highlights the
importance of risk stratification in this patient population
considering that people with HIV are twice as likely to
have cardiovascular events than those without HIV.22
Although most studies evaluating the RR of cardio
vascular disease adjusted for risk factors for cardio
vascular disease, a substantial possibility of residual con
founding remains. Furthermore, there was substantial
publication bias in the literature, which might have
influenced the risk estimates. However, there was little
attenuation of the RRs when analysis was restricted to
studies without moderate to high risk of bias or after
accounting for publication bias using the trim and fill
method. Additionally, we pooled RR estimates of
myocardial infarction or stroke to estimate the PAF and
combined this with the DALYs for ischaemic heart
disease and cerebrovascular disease to estimate the
burden of cardiovascular disease attributable to HCV. We
were unable to estimate the burden of angina or
peripheral artery disease attributable to HCV since these
conditions are often diagnosed in the outpatient setting
and are less likely to be captured by electronic health
record systems. Therefore, it is possible that we have
underestimated the cardiovascular burden associated
with HCV. However, the 2010 Global Burden of Disease
study24,71 showed that angina and peripheral artery disease
contributed a relatively small proportion of the overall
cardiovascular disease burden. The studies included in
this meta-analysis are likely to be exposed to a degree of
outcome misclassification bias because most studies
used routine diagnostic coding to define cardiovascular
events rather than clinical adjudication. All of the
included studies were observational studies, and thus we
are unable to establish causality.
The underlying pathophysiological mechanism for the
association between HCV and cardiovascular disease
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remains unclear.15 HCV infection has been associated
with conditions such as type 2 diabetes, a well known
cardiovascular risk factor.72 Evidence has emerged
showing direct effects of HCV on the development of
atherosclerosis,73 beyond that attributable to metabolic
derangements alone. Chronic HCV infection results in a
chronic state of immune stimulation and inflammation
evidenced by increased circulating levels of proinflam
matory cytokines, such as interleukin 6, tumour necrosis
factor-α, C-reactive protein, and fibrinogen, all of which
are associated with the development of atherosclerotic
cardiovascular disease.32,74,75 Interferon-based antiviral
treatments for HCV reduce markers of inflammation,
endothelial dysfunction, and diabetes mellitus.76–78
Sustained viral response with direct-acting antivirals have
also been associated with a lower risk of cardiovascular
events.79 Whether eradication of HCV infection reduces
future risk of adverse cardiovascular events should be
further explored in randomised controlled trials of directacting antivirals to investigate this finding.
The link between HCV and cardiovascular disease
has important implications for the formulation of
health policies and resource allocation, particularly in
regions with limited health-care resources, where
chronic HCV infection remains prevalent and cardio
vascular disease burden is increasing. Globally,
prevalence of HCV is projected to increase substantially,
particularly in LMICs, as a result of transmission via
unsafe health-care related injections and injection drug
use.9–11 Consequently, mortality due to hepatic and
extrahepatic complications of HCV is likely to increase
considerably if efforts to improve early testing and
treatment are not implemented. A disproportionate
burden of cardiovascular disease is borne by LMICs,
where currently more than 80% of the global burden is
concentrated.80 Our estimates suggest that more than
90% of the global cardiovascular burden attributable to
HCV occurs in LMICs.
The introduction of direct-acting antiviral therapies
with the ability to achieve sustained virological response
in more than 90% of treated individuals should be a cause
for optimism. These new therapeutic options enable the
prevention of both hepatic and extrahepatic complications
of HCV infection with a shorter duration of treatment
and fewer adverse events than previous generations of
antiviral therapies. However, at present, public health
programmes and access to health-care services for people
with HCV lags behind other comparable infectious
diseases, such as HIV or malaria.1 The provision of directacting antiviral therapies in patients with HCV infection
remains low on the global scale, with only one in
15 patients1 currently being treated, the majority of whom
reside in high-income countries.81,82 To have the greatest
impact on HCV morbidity and mortality, the delivery of
curative HCV treatment needs to be coupled with efficient
health systems to provide chronic care services for
patients with both hepatic and extrahepatic complications
802

of HCV. Considering our study findings, investment in
greater strategic integration and linkage of viral hepatitis
services with other relevant services, including
cardiovascular disease prevention, might be a costeffective method of facilitating the prevention and
management of concurrent major health conditions.
These innovative approaches to health-care delivery
might require further research to evaluate feasibility and
efficacy in a real-world clinical setting.
People with HCV have a higher risk of developing
cardiovascular disease than those without HCV. HCV
accounted for 1·5 million DALYs due to cardiovascular
disease worldwide in 2015, with the highest burden in
South Asia, eastern Europe, north Africa, and the Middle
East. Most of the disease burden is borne by LMICs,
where HCV prevalence is projected to rise substantially.
Our findings are of public health importance and could
inform future research and health-care policies to
improve risk stratification and treatment strategies aimed
at reducing the combined global burden of HCV and
extrahepatic sequelae such as cardiovascular disease.
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